RobertJanssenMD

Physician

Dr. Janssen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Pennsylvania Health SystemResidency, Neurology, 1979 - 1985
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1978 - 1979
Keck School of Medicine of the University of Southern CaliforniaClass of 1978

PubMed

127 citations
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, Leo I. Gordon, Jonathan W. Friedberg
Cancer Discovery. 2018-08-28
14 citations
Implementing HIV Screening
Robert S. Janssen
Clinical Infectious Diseases. 2007-12-15
13 citations
Human T-cell lymphotropic virus I and adult T-cell leukemia: Report of a cluster in North Carolina
J. Brice Weinberg, Richard A. Spiegel, Dale L. Blazey, Robert S. Janssen, Jonathan E. Kaplan
The American Journal of Medicine. 1988-07-01

Dynavax Technologies (DVAX) Q2 2020 Earnings Call TranscriptAugust 7th, 2020
Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing HemodialysisApril 28th, 2020
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (Pembrolizumab); Data Presented Today at the 2019 ASCO Annual MeetingJune 3rd, 2019
Join now to see all